Solve JPS

Celestine “Cee Cee” Schnugg is a Silicon Valley venture capitalist and the Founding Managing Partner of Boom Capital, an early-stage venture firm investing in life sciences and frontier technologies. Before founding Boom, Cee Cee was a Partner at Eric Schmidt’s Innovation Endeavors and worked at Apple on the environmental and human rights team.

Motivated by her personal journey as a patient advocate and mother, Cee Cee founded Solve JPS and Solve Polyposis—research and advocacy initiatives dedicated to uncovering biological drivers and advancing the standard of care for polyposis syndromes. Her mission is to accelerate scientific discovery and transform outcomes for patients and families worldwide.

To further this mission, Cee Cee established Project Atlas, a cancer interception foundation focused on accelerating translational research for rare pediatric conditions. Initiatives like Rare Team 6—a multidisciplinary operative—pursue answers for the undruggable and the undiagnosed, while building disease-specific biobanks that harness the decade’s most powerful technologies to cure the incurable by 2035.

Dr. Snyder’s pioneering work in the field has fundamentally reshaped our understanding of the human genome, its role in disease predisposition, and how this knowledge can be leveraged to transform healthcare. 

With a multidisciplinary approach to science, Dr. Snyder’s expertise spans genomics, genetics, systems biology, and precision medicine. His work has focused on the development and application of advanced genomic technologies to study hereditary conditions, including familial adenomatous polyposis (FAP) and other cancer predisposition syndromes. Through his research, Dr. Snyder aims to elucidate the molecular and genetic underpinnings of these conditions, providing actionable insights that can enhance early detection, prevention, and personalized treatment strategies. 

Dr. Snyder has been a driving force in the integration of omics data into personalized medicine. He was one of the first to demonstrate the feasibility and utility of using multi-omics approaches— combining genomics, transcriptomics, proteomics, and metabolomics—to create a detailed and dynamic view of human health. This approach allows him to study complex genetic disorders, such as FAP, in unprecedented detail, revealing how changes at the molecular level can influence disease risk and progression. 

A hallmark of Dr. Snyder’s research has been the use of whole-genome sequencing (WGS) and other high-throughput technologies to uncover genetic variations associated with hereditary conditions. His lab has developed cutting-edge tools to identify rare and novel mutations that contribute to cancer risk in individuals and families. For conditions like FAP, which is characterized by the development of numerous polyps in the gastrointestinal tract and a high risk of colorectal cancer, these tools are instrumental in advancing precision diagnostics and interventions. 

Dr. Snyder’s work has not only led to significant discoveries about genetic disorders but has also helped shape the emerging field of digital health. His research has expanded to include the use of wearable devices and real-time monitoring systems to track physiological changes and identify early signs of disease. This innovative approach to health monitoring has the potential to transform how hereditary conditions like FAP are managed, providing patients and clinicians with continuous, personalized insights into their health status. 

As Director of the Center for Genomics and Personalized Medicine, Dr. Snyder has spearheaded initiatives to bring genomic technologies to the clinic, making precision medicine accessible to a broader population. His leadership has been pivotal in fostering collaborations between academia, industry, and healthcare providers to translate research findings into practical solutions for patients. 

In addition to his academic achievements, Dr. Snyder is an advocate for public engagement in genomics and personalized medicine. He has worked tirelessly to promote genetic literacy among the public, emphasizing the importance of understanding personal genomic data and its implications for health. His vision is to empower individuals with the knowledge and tools to take control of their health, making medicine more predictive, preventive, and personalized.